Aralez Pharmaceuticals Inc. announced the national commercial launch of Zontivity (vorapaxar) in the U.S. will commence this week. Zontivity is the antiplatelet therapy that inhibits PAR-1-mediated platelet aggregation in response to thrombin. Zontivity is a once-daily agent indicated for the reduction of thrombotic CV events in patients with a history of myocardial infarction (MI) or in patients with peripheral arterial disease (PAD), and should be used in combination with daily aspirin and/or clopidogrel according to their indications or standard of care. Zontivity is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). Zontivity should not be used in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH), or active pathological bleeding. Zontivity has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).